GFAP and amyloidosis: For instance, CSF GFAP is a better diagnostic biomarker in AxD whereas plasma GFAP has been demonstrated to outperform CSF GFAP for differentiation of amyloid‐positive and amyloid‐negative individuals in the context of AD.